{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-gord/prescribing-information/proton-pump-inhibitors/","result":{"pageContext":{"chapter":{"id":"bda71033-db69-5e58-977e-9d415fe4f646","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors","depth":2,"htmlHeader":"<!-- begin field e171e87d-9cc3-4d17-ba8a-fc3a240a3c7a --><h2>Proton pump inhibitors</h2><!-- end field e171e87d-9cc3-4d17-ba8a-fc3a240a3c7a -->","summary":"","htmlStringContent":"<!-- begin item b131e376-d2f7-4f8a-938d-0718f58ba916 --><!-- end item b131e376-d2f7-4f8a-938d-0718f58ba916 -->","topic":{"id":"83831d3c-e98d-5e82-9fb9-cbd189e834d5","topicId":"8116d56b-de40-4191-af22-5152cc8f533c","topicName":"Dyspepsia - proven GORD","slug":"dyspepsia-proven-gord","lastRevised":"Last revised in April 2017","chapters":[{"id":"2b894900-36e2-56c8-9d00-aea95f9acd57","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"491fd89e-ec21-5541-b37c-3579bd40472f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6d91073e-8bb8-57e8-8ebf-c1b2832b3377","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69955f21-cf75-5568-9c39-b6894659d140","slug":"changes","fullItemName":"Changes"},{"id":"69e41821-9e9f-506e-bf29-9bb662d19fc5","slug":"update","fullItemName":"Update"}]},{"id":"a5332092-2e76-52c3-9c78-c55c73be1c36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ac987149-bd5e-543a-8025-d0a50c72b165","slug":"goals","fullItemName":"Goals"},{"id":"c282f1cd-c0cd-5cc2-b030-047fa174fc2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"35e91b3d-56f5-5130-8d0e-f0ad612196a3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fac73702-952e-57cf-a136-d52c4400cf78","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8add7bfe-1e06-5768-958d-3c09d529c285","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bb66df20-4142-59d4-913e-cf945ca4dacc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0449fde-d38f-58a1-aee2-098d0ab6ff60","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0a206efc-7aca-58e6-8462-5278f905b372","slug":"definition","fullItemName":"Definition"},{"id":"ce8c37c8-0936-52a2-87a7-0cbf130e1ce3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e1423a90-52a5-592c-ba4d-7f5a420ac54a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cac2f410-0ab9-55d6-8bb8-acbe7735bd9c","slug":"complications","fullItemName":"Complications"},{"id":"9047f011-fcc3-521a-a802-30ac67c85c10","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a4a2f3e7-53b3-50ce-b717-6a6e8e5a219d","fullItemName":"Management","slug":"management","subChapters":[{"id":"6898f6b1-0345-5601-a084-c0f92474d0c9","slug":"dyspepsia-proven-gord","fullItemName":"Scenario: Dyspepsia - proven GORD"}]},{"id":"adea4c6d-b925-5d85-92be-9d322d882faf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"bda71033-db69-5e58-977e-9d415fe4f646","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"15ddfd64-70ae-5a0e-b1ca-6b8811278010","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"}]},{"id":"dc717df5-19a4-5e7d-8391-be3e281ebdc8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"70508c23-67ec-5f56-b6cd-a9612c7e4e9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"713a3147-c4ed-5200-a0ab-51e195929400","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a10b2f69-154b-5dcc-8599-ae8de77e7eda","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6155a413-aefc-5575-b07c-111ad7697022","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73cf98a-26ab-5f78-b8e4-d24d5a849283","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"94379789-e6c4-55fa-b460-965e551f4ea7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"64699d48-46e4-5ff1-97c0-8e280c75065c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"adea4c6d-b925-5d85-92be-9d322d882faf","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"f486fba5-4561-53f4-b7f2-0894ce3fd1d8","slug":"choice-of-proton-pump-inhibitor","fullItemName":"Choice of proton pump inhibitor","depth":3,"htmlHeader":"<!-- begin field 6f7da003-5713-460e-ba98-2ac35002a4d7 --><h3>Choice of proton pump inhibitor</h3><!-- end field 6f7da003-5713-460e-ba98-2ac35002a4d7 -->","summary":"","htmlStringContent":"<!-- begin item acba560f-b5b1-459e-9b8b-2f900353addc --><!-- begin field eeae2b7e-9ee6-4f11-a29e-9d8f1699556f --><ul><li>Table 1 shows the recommended doses of proton pump inhibitors (PPIs) for the management of people with gastro-oesophageal reflux disease (GORD) and severe oesophagitis.</li></ul><p><strong>Table 1</strong><strong>. </strong>PPI doses for management of GORD and severe oesophagitis symptoms.</p><table><thead><tr><th colspan=\"1\"><p>PPI</p></th><th colspan=\"1\"><p>Full or standard dose</p></th><th colspan=\"1\"><p>Low dose (on-demand dose)</p></th><th colspan=\"1\"><p>Double dose</p></th></tr></thead><tbody><tr><td colspan=\"1\">Omeprazole</td><td colspan=\"1\">20 mg once a day (40 mg once a day if severe oesophagitis)</td><td colspan=\"1\">* 10 mg once a day (20 mg once a day if severe oesophagitis)</td><td colspan=\"1\">40 mg once a day (40 mg twice a day if severe oesophagitis)</td></tr><tr><td colspan=\"1\">Lansoprazole</td><td colspan=\"1\">30 mg once a day</td><td colspan=\"1\">15 mg once a day</td><td colspan=\"1\">* 30 mg twice a day</td></tr><tr><td colspan=\"1\">Pantoprazole</td><td colspan=\"1\">40 mg once a day</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">* 40 mg twice a day</td></tr><tr><td colspan=\"1\">Rabeprazole</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">10 mg once a day</td><td colspan=\"1\">* 20 mg twice a day</td></tr><tr><td colspan=\"1\">Esomeprazole</td><td colspan=\"1\">† 20 mg once a day (40 mg once a day if severe oesophagitis)</td><td colspan=\"1\">Not available (20 mg once a day if severe oesophagitis)</td><td colspan=\"1\">‡ 40 mg once a day (40 mg twice a day if severe oesophagitis)</td></tr><tr><td colspan=\"4\">Doses in brackets are specifically for use in severe oesophagitis.</td></tr><tr><td colspan=\"4\">Doses should be given 30 minutes before breakfast and (if needed) 30 minutes before the evening meal, to provide optimal control of gastric pH.</td></tr><tr><td colspan=\"4\">* Off-label dose for GORD.</td></tr><tr><td colspan=\"4\">† This is lower than the licensed starting dose in GORD, but is considered to be dose-equivalent to other PPIs.</td></tr><tr><td colspan=\"4\">‡ This dose is recommended for double dose, because the 20 mg dose of esomeprazole is considered to be equivalent to omeprazole 20 mg.</td></tr><tr><td colspan=\"4\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>]</td></tr></tbody></table><!-- end field eeae2b7e-9ee6-4f11-a29e-9d8f1699556f --><!-- end item acba560f-b5b1-459e-9b8b-2f900353addc -->","subChapters":[]},{"id":"a40bc8cd-b6c2-5bbe-b77a-aa8d3cc1fe30","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0624b9f3-db50-42cd-9726-f3c60d64221d --><h3>Contraindications and cautions</h3><!-- end field 0624b9f3-db50-42cd-9726-f3c60d64221d -->","summary":"","htmlStringContent":"<!-- begin item 421af79f-e515-4fbc-a733-c43ac3979f99 --><!-- begin field 914cf3ea-d0e6-4b94-a3ed-6c38a5daaa36 --><ul><li><strong>Proton pump inhibitors (PPIs) should not be prescribed to people:</strong><ul><li>With alarm symptoms before endoscopy, as PPIs may mask the symptoms of upper gastrointestinal malignancy. If the person is already taking a PPI and subsequently needs an endoscopy, the PPI should be stopped at least 2 weeks before the procedure.</li></ul></li><li><strong>PPIs should be prescribed with caution to people:</strong><ul><li>At risk of osteoporosis — the person should maintain an adequate intake of calcium and vitamin D, and if necessary, be given additional bone-sparing therapy.</li><li>At risk of hypomagnesaemia — if possible, magnesium levels should be checked before starting PPI therapy and intermittently during long-term treatment, for example if the person is prescribed drugs that can cause hypomagnesaemia, such as digoxin and diuretics.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">MHRA, 2012a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">BNF 72, 2016</a>]</p><!-- end field 914cf3ea-d0e6-4b94-a3ed-6c38a5daaa36 --><!-- end item 421af79f-e515-4fbc-a733-c43ac3979f99 -->","subChapters":[]},{"id":"95f98761-7bfb-5d6d-8dc4-ef95188db919","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9a95e05c-4bea-4473-94da-273a0d24d47d --><h3>Adverse effects</h3><!-- end field 9a95e05c-4bea-4473-94da-273a0d24d47d -->","summary":"","htmlStringContent":"<!-- begin item bf137de2-83c7-4435-a2f9-f0188a4e0746 --><!-- begin field ecf5118a-f455-4ead-b513-cbbe887453cc --><p><strong>Adverse effects of proton pump inhibitors (PPIs) are usually mild and reversible.</strong></p><ul><li>Adverse effects include headache, diarrhoea, nausea, vomiting, abdominal pain, constipation, and dizziness.</li><li>Less common adverse effects include dry mouth, peripheral oedema, sleep disturbance, fatigue, paraesthesia, arthralgia, myalgia, pruritus, and rash.</li><li>Rare or very rare adverse effects include:<ul><li>Subacute cutaneous lupus erythematosus (SCLE), which can occur weeks, months, or years after exposure to a PPI. If suspected discontinue the PPI and seek specialist advice if needed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">MHRA, 2015</a>].</li><li>Taste disturbance, hepatitis, jaundice, depression, confusion, hallucinations, hyponatraemia, leucopenia, leucocytosis, pancytopenia, thrombocytopenia, visual disturbances, sweating, photophobia, and alopecia.</li></ul></li><li>Long-term PPI treatment may be associated with uncommon, serious adverse effects such as:<ul><li>Hypomagnesaemia — symptoms include muscle twitching, tremors, vomiting, fatigue, and loss of appetite. Case reports after one year of PPI therapy, but may occur after 3 months. This usually improves after magnesium replacement therapy and discontinuation of the PPI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">MHRA, 2012a</a>].</li><li>Increased risk of fractures — especially when used at high doses for over a year in the elderly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">MHRA, 2012b</a>].</li><li><em>Clostridium difficile </em>infection — due to the effect of decreasing gastric acidity.</li><li>Rebound acid hypersecretion syndrome — may occur after stopping long-term PPI therapy, although this may be more a theoretical risk than clinical phenomenon.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">BNF 72, 2016</a>]</p><!-- end field ecf5118a-f455-4ead-b513-cbbe887453cc --><!-- end item bf137de2-83c7-4435-a2f9-f0188a4e0746 -->","subChapters":[]},{"id":"ee545f24-1b83-55f4-b75d-f22af320c6bc","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 0a32c52c-bcbb-4cd2-b0e9-bac76d2b1f06 --><h3>Drug interactions</h3><!-- end field 0a32c52c-bcbb-4cd2-b0e9-bac76d2b1f06 -->","summary":"","htmlStringContent":"<!-- begin item 55eab443-dab0-49cf-8e24-c37b39ba39c3 --><!-- begin field b5790094-333b-46ab-8a58-1342bc9e6fac --><p><strong>Possible drug interactions with proton pump inhibitors (PPIs) include:</strong></p><ul><li><strong>Digoxin </strong>— PPIs may cause a small rise in serum digoxin levels (although not considered clinically significant). The manufacturer of lansoprazole suggests that digoxin levels should be monitored if lansoprazole is started or stopped.</li><li><strong>Warfarin </strong>— PPIs can occasionally enhance the effects of warfarin. The<strong> </strong>International Normalized Ratio (INR) should be monitored in people taking warfarin if omeprazole, pantoprazole, or esomeprazole is started or stopped.</li><li><strong>Methotrexate </strong>— PPIs possibly reduce excretion of methotrexate, leading to an increased risk of methotrexate toxicity.</li><li><strong>Phenytoin </strong>— omeprazole and esomeprazole can occasionally enhance the effects of phenytoin.<strong> </strong>The manufacturers recommend that people taking phenytoin are carefully monitored if omeprazole or esomeprazole is started or stopped.</li><li><strong>Azole antifungals </strong>— the absorption of ketoconazole or itraconazole may be reduced during PPI treatment. Dose adjustment of the antifungal drug may be required during long-term PPI treatment.</li><li><strong>Clopidogrel </strong>— omeprazole and esomeprazole reduce the antiplatelet effect of clopidogrel, and concomitant use should be avoided. The other PPIs may also reduce the efficacy of clopidogrel, and this risk should be weighed against the potential benefit of the PPI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">MHRA, 2010</a>].</li><li><strong>Protease inhibitors </strong>— PPIs can significantly affect plasma levels of some protease inhibitor drugs, including:<ul><li>Atazanavir — concurrent use of PPIs and atazanavir is not recommended as the absorption of atazanavir may be affected by a PPI (due to changes in gastric acidity). This may lead to a reduced plasma concentration of atazanavir which may affect its efficacy. If concurrent use is necessary, seek specialist advice.</li><li>Saquinavir — plasma concentration of saquinavir may be increased by PPI treatment, leading to increased risk of adverse effects.</li><li>Tipranavir — concurrent use with omeprazole or esomeprazole is not recommended, as tipranavir may reduce the plasma concentration of the PPI. If concurrent use is necessary, seek specialist advice.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">BNF 72, 2016</a>]</p><!-- end field b5790094-333b-46ab-8a58-1342bc9e6fac --><!-- end item 55eab443-dab0-49cf-8e24-c37b39ba39c3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}